Incident response · Digital health & life sciences
Incident Response Planning for Biotech & Pharma Companies
An incident response plan for a biotech or pharma company has to keep two kinds of clocks running during a breach: the regulatory clocks, such as the seven or fifteen days for a serious adverse drug reaction, and the operational clock of restoring trial or PSP systems. The trigger is usually a hub vendor's breach notice, a ransomware event at a shared eClinical platform, or the sudden realization that nobody has agreed who notifies patients when the incident happened outside the company's own systems. We build the plan, the roles and the rehearsal that keep both clocks defensible.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What an incident response plan has to cover in this sector
A plan built for a typical company misses the parts of a biotech or pharma incident that don't stop just because security is responding to a breach.
Continuity of adverse-event reporting during an outage
Pharmacovigilance staff still have to identify, assess and report serious adverse drug reactions on statutory timelines even while the systems they normally use are compromised or unavailable.
A clear hub vendor and CRO notification chain
Who notifies patients or investigators when the breach happened at a third party, not the sponsor, decided in advance rather than argued about while the clock is running.
Restoration priority for trial-critical systems
EDC, eTMF and IRT systems need a recovery sequence that balances containment against the operational cost of a study going dark, a tradeoff most generic IR plans never address.
Case-narrative and safety-database integrity during recovery
Adverse-event records have to remain complete and traceable through the incident, not reconstructed afterward from memory or scattered email threads.
Communication to partners and the board mid-incident
A licensing partner or investor will ask what happened and what the company did about it, often before the incident is even fully contained, and the plan needs a ready answer.
Regulatory map
The regulatory clocks an incident response plan has to keep running
None of the statutory deadlines in this sector pause because a security incident is underway, which is exactly why they have to be built into the plan itself.
Serious unexpected ADR reporting in trials
Seven days for a fatal or life-threatening reaction, fifteen days otherwise — a countdown the plan has to keep moving even while the rest of the response is still underway.
A fifteen-day clock for marketed products too
The fifteen-day window for reporting a serious reaction on an already-marketed product applies just the same, whether or not the systems used to identify it are currently under attack.
OPC real-risk breach reporting
Organizations must report a breach to the federal regulator and affected individuals when it creates a real risk of significant harm, a judgment call the plan has to guide someone through under pressure.
Mandatory breach-record keeping
Every breach of safeguards has to be logged and kept for twenty-four months, whether or not it met the threshold for formal reporting, a discipline the plan should build in from the start.
What goes wrong
The incident scenarios this plan is built to answer
These are the specific situations that expose the gap between a generic security incident plan and one built for trial, PSP and IP data.
A hub vendor breach that reaches Canadian patients slowly
When a PSP hub is compromised, delayed notification to the patients whose diagnoses and medications were exposed has already drawn public criticism and litigation in this sector.
Ransomware forcing trial sites back to paper
A 2020 attack on a shared eClinical vendor pushed sites onto manual data capture mid-study, the exact scenario a plan's system-restoration priorities are meant to address.
Adverse-event data mishandled during the response itself
Case narratives forwarded by email or copied into ad hoc spreadsheets while the primary safety database is down create a second, self-inflicted privacy incident on top of the first.
Manufacturing OT disruption halting GMP production
Ransomware reaching operational technology on a production line can stop GMP-controlled manufacturing outright, a scenario a plan should treat as a business-continuity event, not just a security one.
Our incident response for biotech & pharma companies
What our incident response planning covers for a biotech or pharma company
A documented plan built around your actual trial, PSP and IP data rather than a downloaded template nobody has customized.
A custom plan documenting roles and triggers
Clear escalation paths and decision rights covering trial-system incidents, hub or CRO vendor breaches, and IP-theft scenarios, reflecting how your organization actually operates.
Regulatory reporting playbooks built into the plan
Step-by-step guidance for the ADR reporting windows and the OPC's real-risk assessment, so the person on call during an incident isn't looking these up for the first time.
Vendor and hub notification protocols
Documented expectations for who notifies whom when a breach originates at a CRO, hub or specialty pharmacy, matched against what your existing contracts actually say.
Ongoing updates as vendors and systems change
Revisions to the plan as new CRO relationships, hub vendors or cloud systems come online, so it reflects your current environment rather than the one that existed when it was written.
How the engagement runs
How we build an incident response plan for this sector
Built from your actual systems and vendor contracts, then tested before it's ever needed for real.
Step 1
Assess the current gap
We review what exists today against the trial, PSP and IP scenarios most likely to occur, and identify where roles, contracts or reporting steps are missing.
Step 2
Draft roles and escalation paths
The plan assigns clear ownership for containment, regulatory reporting and partner communication, matched to your actual team structure.
Step 3
Build in the regulatory clocks
ADR reporting windows and OPC breach-assessment steps are written directly into the plan as triggers, not left as a separate reference document nobody opens under pressure.
Step 4
Rehearse it
A tabletop exercise walks the team through a hub-vendor-breach or ransomware scenario, surfacing gaps while the stakes are still theoretical.
What it costs
What drives incident response planning cost for a biotech or pharma company
Cost depends on how many distinct incident paths need their own protocol — trial-system outages, hub vendor breaches, IP theft and manufacturing OT events each require different roles and different regulatory steps — and how many CRO, hub and cloud vendor contracts need to be reviewed against the plan.
A single-trial discovery company with no live PSP typically needs a narrower plan than a clinical-stage company running several vendor relationships and an active patient program. We scope pricing after reviewing your current vendor contracts and system landscape, and can include a tabletop exercise as part of the engagement.
Biotech & Pharma Companies: Incident response questions, answered
That depends entirely on what your hub services agreement says, which is exactly why the plan should document the answer before an incident, not during one. In practice, either party can end up responsible depending on contract terms, and an incident response plan should specify the default assumption and the escalation path if the vendor is slow to act.
The plan needs a documented fallback process — an alternate way to identify, assess and submit serious adverse drug reaction reports — that does not depend on the same system that's down. Pharmacovigilance staff need to know that fallback exists and have practiced it, not discover it exists only when they need it.
Possibly, yes. If personal information you are accountable for was exposed through a vendor's systems, your organization's own reporting duty under the real-risk-of-significant-harm standard can still apply, separate from whatever the vendor itself is obligated to do. The plan should walk whoever is on call through that assessment step by step.
Yes, if manufacturing is part of the business. GMP production disruption is a business-continuity event with its own restoration priorities and stakeholders, distinct from a trial-system outage or a PSP data breach, and folding all three into one generic playbook usually means none of them gets a workable response.
At least annually, and again after any material change — a new hub vendor, a new trial system, a new manufacturing line. A plan that has never been rehearsed tends to reveal its gaps for the first time during an actual incident, which is the worst possible moment to discover them.
More for biotech & pharma companies
Other services for this niche
About this service
Answers & guides
- Do you need an incident response plan, and what should it include?
- What should I do after a data breach?
- When should you hire a privacy breach response consultant?
- Writing an Incident Response Plan Your Team Will Actually Use
- The First 24 Hours After a Privacy Breach: A Canadian Response Playbook
- PIPEDA Breach Notification and Record-Keeping: What to Get Right
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.